These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2218966)

  • 1. [Aspirin against aging? For whom and how much?].
    Oelz O; Meier PJ
    Ther Umsch; 1990 Aug; 47(8):648-52. PubMed ID: 2218966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acetylsalicylic acid in arterial circulatory disorders. Which dosage in which indication?].
    Ranke C; Creutzig A; Alexander K
    Dtsch Med Wochenschr; 1994 Jun; 119(22):815-21. PubMed ID: 8205945
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Coronary disease: benefits of aspirin. What dose for which disease?].
    Michel PL
    Ann Cardiol Angeiol (Paris); 1994 Apr; 43(4):204-10. PubMed ID: 8024235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Low dose acetylsalicylic acid in secondary prevention of stroke].
    Deecke L; Zeiler K
    Wien Klin Wochenschr; 1993; 105(17):485-7. PubMed ID: 8212707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland.
    Rodondi N; Cornuz J; Marques-Vidal P; Butler J; Hayoz D; Pécoud A; Paccaud F; Waeber G; Vollenweider P
    Prev Med; 2008 Feb; 46(2):137-44. PubMed ID: 17904211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
    Rosa A; Canaple S
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1563-8. PubMed ID: 9092419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary prevention of stroke: does dipyridamole add to aspirin?
    Lowenthal A; Buyse M
    Acta Neurol Belg; 1994; 94(1):24-34. PubMed ID: 8140884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study.
    Linos A; Worthington JW; O'Fallon W; Fuster V; Whisnant JP; Kurland LT
    Mayo Clin Proc; 1978 Sep; 53(9):581-6. PubMed ID: 682687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Primary prevention of intermittent claudication and frequently associated arteriopathies].
    Monti M
    Ther Umsch; 1987 Sep; 44(9):625-36. PubMed ID: 3313792
    [No Abstract]   [Full Text] [Related]  

  • 13. [Aspirin and coronary heart disease].
    Dubach P
    Schweiz Rundsch Med Prax; 1988 Sep; 77(37):961-2. PubMed ID: 3175422
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
    Maree AO; Curtin RJ; Dooley M; Conroy RM; Crean P; Cox D; Fitzgerald DJ
    J Am Coll Cardiol; 2005 Oct; 46(7):1258-63. PubMed ID: 16198840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Platelet antiaggregants and coronary pathology].
    Castaigne A; Duval-Moulin AM; Dutoit C
    Rev Prat; 1989 Nov; 39(25):2228-33. PubMed ID: 2688043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
    Antiplatelet Trialists' Collaboration
    Br Med J (Clin Res Ed); 1988 Jan; 296(6618):320-31. PubMed ID: 3125883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aspirin in the prevention of cardiovascular and cerebrovascular disease.
    Long K; Long R
    Nurse Pract Forum; 1992 Jun; 3(2):58-9. PubMed ID: 1392672
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
    Cruz-Fernández JM; López-Bescós L; García-Dorado D; López García-Aranda V; Cabadés A; Martín-Jadraque L; Velasco JA; Castro-Beiras A; Torres F; Marfil F; Navarro E
    Eur Heart J; 2000 Mar; 21(6):457-65. PubMed ID: 10681486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.